Physician profile
Julia A Kasper
NPI 1972875292
$7,199.54
in general payments reported to CMS, 2019-2025
34 companies · $872 in 2025
The $872 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $200 · 2021: $869 · 2022: $1,321 · 2023: $2,013 · 2024: $1,925 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,809.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.28 | 2021-2025 | |
| Novo Nordisk INC | $1,334.53 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $772.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.08 | 2020-2025 | Breztri, Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $437.38 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $321.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $227.81 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $218.38 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $213.78 | 2021-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $176.24 | 2022-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.01 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $131.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $101.46 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $83.12 | 2021-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $79.94 | 2023-2024 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $76.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.58 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $73.38 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $70.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.61 | 2024-2025 | Xifaxan |
| Biogen, INC. | $61.11 | 2024 | Skyclarys, Leqembi |
| Eisai INC. | $54.64 | 2021-2025 | |
| Corium, LLC | $45.31 | 2023-2024 | Azstarys |
| Amarin Pharma, INC. | $37.03 | 2021 | |
| Optinose US, INC. | $35.72 | 2024 | |
| Bausch Health US, LLC | $31.80 | 2022 | |
| Merck Sharp & Dohme LLC | $30.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.39 | 2022 | |
| Axsome Therapeutics, INC. | $25.01 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $23.52 | 2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $23.01 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $18.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.45 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.